We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
Read MoreHide Full Article
Stryker (SYK - Free Report) recently announced the expansion of its Foot & Ankle portfolio with the introduction of two cutting-edge products — the Osteotomy Truss System (“OTS”) and the Ankle Truss System (“ATS”). Acquired from 4WEB Medical, these new products are designed to enhance surgical precision and improve patient outcome. Both products will be featured at the American Orthopaedic Foot & Ankle Society Annual Meeting in Vancouver during Sept. 11-14, 2024.
The addition of the ATS and the integration of Artelon demonstrate SYK’s focus on providing surgeons with improved orthopaedic solutions to achieve the best possible patient outcome. The company remains dedicated to continually advancing its offerings to meet the evolving needs of customers in all foot and ankle procedures.
SYK’s Infinity Total Ankle System is a market leader in low-profile ankle implants and has demonstrated outstanding long-term results, with a 98.8% survivorship rate at two years and 95.9% at seven years. The system's anatomically contoured components ensure that patients maintain mobility and joint function, solidifying Stryker’s reputation as a leader in total ankle replacement. The new systems will likely help the company to solidify its leadership position in the segment.
Stryker’s share price closed 0.4% higher on Sept. 11 following the announcement of the news. In the past six months, SYK’s shares have risen 2.6% compared with the industry’s growth of 6.4%. The S&P 500 has gained 6.5% in the same time frame.
Image Source: Zacks Investment Research
SYK’s Innovative Technologies to Address Surgical Needs
The ATS incorporates the Arthrosphere and Arthrocube implants, which are designed to restore limb length while ensuring structural integrity during tibiotalocalcaneal fusions. One of the standout features of ATS is its Truss Implant Technology, which offers an open architecture that not only supports structural stability but also promotes fusion in patients. The system is compatible with Stryker’s T2 Ankle Arthrodesis Nail and Valor Hindfoot Fusion Nail, offering a versatile and comprehensive solution for complex ankle surgeries.
Available in three distinct shapes, the ATS implants are designed to provide surgeons with flexible options, ensuring faster scheduling for patients who require immediate ankle fusion procedures. This innovation marks a significant leap in enabling surgeons to restore both form and function in a precise and efficient manner.
Meanwhile, the OTS includes Cotton, Evans and Utility wedges, delivering a comprehensive solution for various osteotomy needs in the foot and ankle. OTS is currently available for internal bone fixation and osteotomies in the foot and ankle.
Stryker will also showcase its Artelon Flexband, a next-generation biomaterial designed to aid the healing of soft tissues by restoring their natural strength and elasticity. This innovative material is part of the company’s ongoing commitment to driving innovation in orthopedic procedures.
Favorable Industry Prospects for SYK
Per a report by Markets and Markets, the global foot and ankle device market size was estimated to be $4.4 billion in 2022 and is expected to witness a CAGR of 5.9% until 2032 to reach $7.8 billion.
Given the market potential, SYK’s ATC and OTC devices are likely to provide a boost to the company’s business.
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Quest Diagnostics Incorporated (DGX - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 24.2%. Its shares have risen 11.4% compared with the industry’s 7.7% growth in the past six months.
Quest Diagnostics, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.2%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.
Quest Diagnostics’ shares have risen 18.6% compared with the industry’s 7.7% growth in the past six months.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific’s shares have rallied 25.6% compared with the industry’s 6.5% growth in the past six months.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
Stryker (SYK - Free Report) recently announced the expansion of its Foot & Ankle portfolio with the introduction of two cutting-edge products — the Osteotomy Truss System (“OTS”) and the Ankle Truss System (“ATS”). Acquired from 4WEB Medical, these new products are designed to enhance surgical precision and improve patient outcome. Both products will be featured at the American Orthopaedic Foot & Ankle Society Annual Meeting in Vancouver during Sept. 11-14, 2024.
The addition of the ATS and the integration of Artelon demonstrate SYK’s focus on providing surgeons with improved orthopaedic solutions to achieve the best possible patient outcome. The company remains dedicated to continually advancing its offerings to meet the evolving needs of customers in all foot and ankle procedures.
SYK’s Infinity Total Ankle System is a market leader in low-profile ankle implants and has demonstrated outstanding long-term results, with a 98.8% survivorship rate at two years and 95.9% at seven years. The system's anatomically contoured components ensure that patients maintain mobility and joint function, solidifying Stryker’s reputation as a leader in total ankle replacement. The new systems will likely help the company to solidify its leadership position in the segment.
Stryker’s share price closed 0.4% higher on Sept. 11 following the announcement of the news. In the past six months, SYK’s shares have risen 2.6% compared with the industry’s growth of 6.4%. The S&P 500 has gained 6.5% in the same time frame.
Image Source: Zacks Investment Research
SYK’s Innovative Technologies to Address Surgical Needs
The ATS incorporates the Arthrosphere and Arthrocube implants, which are designed to restore limb length while ensuring structural integrity during tibiotalocalcaneal fusions. One of the standout features of ATS is its Truss Implant Technology, which offers an open architecture that not only supports structural stability but also promotes fusion in patients. The system is compatible with Stryker’s T2 Ankle Arthrodesis Nail and Valor Hindfoot Fusion Nail, offering a versatile and comprehensive solution for complex ankle surgeries.
Available in three distinct shapes, the ATS implants are designed to provide surgeons with flexible options, ensuring faster scheduling for patients who require immediate ankle fusion procedures. This innovation marks a significant leap in enabling surgeons to restore both form and function in a precise and efficient manner.
Meanwhile, the OTS includes Cotton, Evans and Utility wedges, delivering a comprehensive solution for various osteotomy needs in the foot and ankle. OTS is currently available for internal bone fixation and osteotomies in the foot and ankle.
Stryker will also showcase its Artelon Flexband, a next-generation biomaterial designed to aid the healing of soft tissues by restoring their natural strength and elasticity. This innovative material is part of the company’s ongoing commitment to driving innovation in orthopedic procedures.
Favorable Industry Prospects for SYK
Per a report by Markets and Markets, the global foot and ankle device market size was estimated to be $4.4 billion in 2022 and is expected to witness a CAGR of 5.9% until 2032 to reach $7.8 billion.
Given the market potential, SYK’s ATC and OTC devices are likely to provide a boost to the company’s business.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
SYK’s Zacks Rank and Stocks to Consider
Stryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Quest Diagnostics Incorporated (DGX - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 24.2%. Its shares have risen 11.4% compared with the industry’s 7.7% growth in the past six months.
Quest Diagnostics, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.2%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.3%.
Quest Diagnostics’ shares have risen 18.6% compared with the industry’s 7.7% growth in the past six months.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific’s shares have rallied 25.6% compared with the industry’s 6.5% growth in the past six months.